Corcept Therapeutics (CORT) Receivables - Net (2012 - 2026)

Corcept Therapeutics (CORT) has 15 years of Receivables - Net data on file, last reported at $39.1 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables - Net fell 36.8% year-over-year to $39.1 million; the trailing twelve-month figure through Mar 2026 stood at $39.1 million (down 36.8% YoY), and the FY2025 full-year result was $59.8 million, up 10.76% from the prior year.
• Receivables - Net declined to $39.1 million in Q1 2026, from $59.8 million in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $69.6 million in Q3 2025 to a low of $27.2 million in Q1 2022.
• A 5-year average of $45.9 million and a median of $41.1 million in 2023 frame the typical range for Receivables - Net.
• Across the five-year window, Receivables - Net surged 88.95% in 2024 and tumbled 36.8% in 2026, its largest moves.
• Tracing CORT's Receivables - Net over 5 years: stood at $31.1 million in 2022, then jumped by 32.41% to $41.1 million in 2023, then surged by 31.26% to $54.0 million in 2024, then gained by 10.76% to $59.8 million in 2025, then plunged by 34.65% to $39.1 million in 2026.
• Business Quant data shows CORT's Receivables - Net at $39.1 million in Q1 2026, $59.8 million in Q4 2025, and $69.6 million in Q3 2025.